Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ecuphar veterinaria (decommissioned) s.l.u. - ketoprofen 300 mg/ml - oral solution - 300 mg/ml - ketoprofen 300 mg/ml - ketoprofen - cattle; pig

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ecuphar veterinaria s.l.u - ketoprofen 150 mg/ml - solution for injection - 150 mg/ml - ketoprofen 150 mg/ml - ketoprofen - cattle; horse; pig

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hong kong ban kah chai med. fty. sdn. bhd. - cortex eucommiae; tea leave; spica prunellae; senna fruit powder; rhizoma atractylodis; radix glycyrrhizae extract; radix et rhizoma rhei; pericarpium citri reticulatae; herba menthae; herba dendrobii -

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; calteridol calcium; trometamol; sodium hydroxide; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; trometamol; calteridol calcium - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of ge for enhancement of magnetic images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; calteridol calcium; trometamol; sodium hydroxide; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; calteridol calcium; trometamol; hydrochloric acid; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years ofage for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: trometamol; sodium hydroxide; calteridol calcium; water for injections; hydrochloric acid - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 yaers of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; caldiamide sodium hydrate; water for injections; sodium hydroxide - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: caldiamide sodium hydrate; water for injections; sodium hydroxide; hydrochloric acid - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularlity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.